SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Standaert David G)
 

Sökning: WFRF:(Standaert David G) > Effects of Levodopa...

  • Chaudhuri, K. RayKing's College Hospital (författare)

Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep : Results from a Meta-Analysis with 24-Month Follow-Up

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • 2022
  • 13 s.

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:a1bf102d-1110-4a13-92b0-197aa5f700af
  • https://lup.lub.lu.se/record/a1bf102d-1110-4a13-92b0-197aa5f700afURI
  • https://doi.org/10.3233/JPD-223295DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:for swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Background: In advanced Parkinson's disease (PD), dyskinesias and non-motor symptoms such as sleep dysfunction can significantly impair quality of life, and high-quality management is an unmet need. Objective: To analyze changes in dyskinesia and non-motor symptoms (including sleep) among studies with levodopa-carbidopa intestinal gel (LCIG) in patients with advanced PD. Methods: A comprehensive literature review identified relevant studies examining LCIG efficacy. Outcomes of interest were dyskinesia (UDysRS, UPDRS IV item 32), overall non-motor symptoms (NMSS), mentation/behavior/mood (UPDRS I), and sleep/daytime sleepiness (PDSS-2, ESS). The pooled mean (95% confidence interval) change from baseline per outcome was estimated for each 3-month interval with sufficient data (i.e., reported by≥3 studies) up to 24 months using a random-effects model. Results: Seventeen open-label studies evaluating 1243 patients with advanced PD were included. All outcomes of interest with sufficient data for meta-analysis showed statistically significant improvement within 6 months of starting LCIG. There were statistically significant improvements in dyskinesia duration as measured by UPDRS IV item 32 at 6 months (-1.10 [-1.69, -0.51] h/day) and 12 months (-1.35 [-2.07, -0.62] h/day). There were statistically and clinically significant improvements in non-motor symptoms as measured by NMSS scores at 3 months (-28.71 [-40.26, -17.15] points). Significant reduction of NMSS burden was maintained through 24 months (-17.61 [-21.52, -13.70] points). UPDRS I scores significantly improved at 3 months (-0.39 [-0.55, -0.22] points). Clinically significant improvements in PDSS-2 and ESS scores were observed at 6 and 12 months in individual studies. Conclusion: Patients with advanced PD receiving LCIG showed significant sustained improvements in the burden of dyskinesia and non-motor symptoms up to 24 months after initiation.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Antonini, AngeloUniversity of Padova (författare)
  • Pahwa, RajeshUniversity of Kansas Medical Center (författare)
  • Odin, PerLund University,Lunds universitet,Neurologi, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Neurology, Lund,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)med-poi (författare)
  • Titova, NataliyaFederal Center of Brain Research and Neurotechnologies of the FMBA of Russia,Pirogov Russian National Research Medical University (RNRMU) (författare)
  • Thakkar, SandeepHoag Hospital Newport Beach (författare)
  • Snedecor, Sonya J.Open Health, New York (författare)
  • Hegde, SaketOpen Health, New York (författare)
  • Alobaidi, AliUniversity of Illinois at Chicago,AbbVie Inc. (författare)
  • Parra, Juan CarlosAbbVie Inc. (författare)
  • Zadikoff, CindyAbbVie Inc. (författare)
  • Bergmann, LarsAbbVie Inc. (författare)
  • Standaert, David G.University of Alabama (författare)
  • King's College HospitalUniversity of Padova (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Parkinson's Disease12:7, s. 2071-20831877-7171

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy